HIV prevention network and operations center
HIV Prevention Trials Network Leadership and Operations Center
This program develops and runs new HIV prevention tools—like long‑acting medicines, combined HIV/contraception products, and antibodies—for people at higher risk such as young adults, women in sub‑Saharan Africa, men who have sex with men, transgender women, sex workers, and people who inject drugs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Family Health International NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11466552 on NIH RePORTER |
What this research studies
From my point of view, this network brings together researchers, clinics, and communities to design and run clinical studies of promising HIV prevention options. They test long‑acting antiretroviral medicines for PrEP, multipurpose products that could prevent HIV and pregnancy or STIs, and antibody‑based approaches, tailoring studies to groups at higher risk. Studies are carried out at sites in the U.S. and around the world, with attention to safety monitoring, community engagement, and making successful tools scalable. The operations center coordinates study logistics, data management, and partnerships with other networks to speed up testing and delivery of effective interventions.
Who could benefit from this research
Good fit: Ideal participants are people at increased risk of acquiring HIV—including young men and women, women in sub‑Saharan Africa, men who have sex with men, transgender women who have sex with men, sex workers, and people who inject drugs—who live near a participating site and are willing to try study prevention products.
Not a fit: People who are not at risk for HIV, those already living with HIV (unless a specific sub‑study includes them), or individuals unable or unwilling to attend a study site are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, this work could lower new HIV infections by making prevention safer, longer‑lasting, and easier to use for people at risk.
How similar studies have performed: Some prevention approaches like daily oral PrEP and injectable long‑acting PrEP have already reduced HIV risk, while multipurpose products and antibody strategies are newer and still being tested for effectiveness.
Where this research is happening
Durham, United States
- Family Health International — Durham, United States (Active)
Researchers
- Principal investigator: Landovitz, Raphael J — Family Health International
- Study coordinator: Landovitz, Raphael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.